Pyxis Oncology, Inc. (PYXS) income statement
PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.41−0.03 (-2.08%)
Close on Nov 18, 2026Market cap $117.61MP/E –Yield –
Pyxis Oncology, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- 82.8%
- Operating margin
- -664.6%
- Net margin
- -640.3%
- Return on equity, FY2025
- -91.4%
Financial strength
- Current ratio
- 1.34
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 68.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 10.28
- Dividend yield
- –
See a number that looks wrong?